
    
      A phase II, randomized, double-blind, placebo-controlled study to:

        1. Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with
           psoriatic arthritis (PsA).

        2. Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of
           subjects with PsA
    
  